From Homeless in the Congo to the Oscars Red Carpet: The Story You Must Read Before Tomorrow




Style News Now





02/23/2013 at 05:40 PM ET



Oscars 2013 Rachel MwanzaCourtesy Rachel Mwanza


One of the best stories from this year’s Oscars ceremony isn’t taking place on screen, but rather on the red carpet.


Rachel Mwanza, the 16-year-old star of the Best Foreign Language Film nominee War Witch, will be joining her fellow nominees in L.A. after obtaining a visa from the war-torn Democratic Republic of the Congo just days before the Oscars.


The young actress was “discovered” by the War Witch team from a documentary called Kinshasa Kids, which portrayed the life of Mwanza and other children living on the streets in the Congo.


Since being cast in the film, in which she plays a child kidnapped and enslaved to a life of guerilla warfare, her life has changed dramatically — from having a home and education paid for to winning a best actress award at the Berlin Film Festival.


And since her flight arrived late Friday night, she needed a red carpet-worthy dress quickly, which is where Rent the Runway stepped in.

The designer rental service rushed Mwanza several dresses to wear to the Independent Spirit Awards Saturday, from which she chose Kate Spade New York’s “Tiebreaker” style, adding Chamak by Priya Kakkar bangles and a Judith Leiber clutch.


“I’m so excited to be in Los Angeles. I’ve never seen the ocean before!” Mwanza tells PEOPLE through a translator. “I’m tired from my long trip, but way too excited to rest!”


She shared exclusive shots with PEOPLE (above) of her trying-on process, including shots of her caretaker “Mama” helping her zip into her final dress, and the many jewels she was sent to choose from.


And it didn’t take much to get Mwanza ready for her high-profile debut: “I’m going to work it on the red carpet,” she says. “I’ve been practicing my poses!”


The one disappointment from her trip so far? No sightings of a certain superstar. “BeyoncĂ© is my favorite in the whole world. Why is she not here?!” Mwanza jokes.


Below, see a shot of Mwanza and her War Witch producers Marie-Claude Poulin and Pierre Even at the Independent Spirit Awards, and be sure to watch her film, which will be On Demand beginning Tuesday and in select theaters March 1.


And keep an eye out for her at the Oscars Sunday night, where she’ll be wearing a top-secret dress made for her by an African designer. Can’t wait to see her poses!


Oscars 2013 Rachel MwanzaCourtesy Rachel Mwanza


–Alex Apatoff


PHOTOS: SEE MORE OSCARS STYLE HERE!


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

New toll lanes open on 10 Freeway









Los Angeles County's venture into toll roads advanced early Saturday with the opening of 14 miles of express lanes on the San Bernardino Freeway — the second project of its type to begin operation in the region since November.


At 12:01 a.m., the Los Angeles County Metropolitan Transportation Authority allowed drivers to travel the 10 Freeway's new high occupancy toll lanes — so-called HOT lanes — between Interstate 605 in El Monte and Alameda Street in downtown Los Angeles.


"This shows we are willing to address traffic, gridlock and congestion in the region," said Los Angeles Mayor and MTA board member Antonio Villaraigosa at a dedication ceremony in El Monte on Friday. "Other cities are going to do this across the county. We are going to see smarter use of highways."





The two westbound and two eastbound "Metro ExpressLanes" will be open to solo motorists who pay a toll, but they will be free for cars carrying at least two passengers.


During peak travel times, however, only carpools of three or more people will be able to use the lanes without paying. Van pools and motorcyclists also can enter the lanes toll free.


Using congestion pricing, motorists will pay anywhere from $0.25 a mile during off-peak periods to $1.40 a mile during the height of rush hour. MTA officials estimate that the average one-way cost should range between $4 and $7.


Setting tolls based on the volume of traffic is designed to maintain speeds of no less than 45 mph in the lanes. If the speed falls below that level, solo motorists will be prohibited from entering the lanes until the minimum speed resumes.


Motorists interested in the express lanes must open a FasTrak account with the MTA and make a $40 deposit to obtain a transponder, an electronic device that automatically bills their accounts whenever the lanes are used. Drivers can adjust the transponder to show how many people are in the vehicle, so the charges can be adjusted. Information is available online at metroexpresslanes.net.


The county marked its entry into the use of tollways on Nov. 10, when the MTA opened its first express lanes along 11 miles of the Harbor Freeway between Adams Boulevard in Los Angeles and the Harbor Gateway Transit Center in the South Bay.


The lanes on both freeways are part of a $210-million demonstration project funded largely by the federal government. It includes upgrading transit and rail stations, 59 new clean-fuel buses, the $60-million El Monte Bus Station, highway ramp improvements and 100 new vanpools.


MTA officials said the express lanes on the 10 and 110 will cost $7 million to $10 million a year to operate, but should generate $18 million to $20 million in revenue, money that can be reinvested in both freeway corridors. So far, more than 100,000 people have obtained transponders for the lanes, officials said.


During the next year, the express-lane projects will be evaluated to determine whether the program should be continued and expanded to other freeways in the county.


"We expect it will be totally successful," said Victor Mendez, head of the Federal Highway Administration. "The project offers commuters a variety of choices, not just the highway."


dan.weikel@latimes.com





Read More..

In Niger, U.S. Troops Set Up Drone Base





WASHINGTON — Opening a new front in the drone wars against Al Qaeda and its affiliates, President Obama announced on Friday that about 100 American troops had been sent to Niger in West Africa to help set up a new base from which unarmed Predator aircraft would conduct surveillance in the region.




The new drone base, located for now in the capital, Niamey, is an indication of the priority Africa has become in American antiterrorism efforts. The United States military has a limited presence in Africa, with only one permanent base, in Djibouti, more than 3,000 miles from Mali, where insurgents had taken over half the country until repelled by a French-led force.


In a letter to Congress, Mr. Obama said about 40 United States military service members arrived in Niger on Wednesday, bringing the total number of those deployed in the country to about 100 people. A military official said the troops were largely Air Force logistics specialists, intelligence analysts and security officers.


Mr. Obama said the troops, who are armed for self-protection, would support the French-led operation that last month drove the Qaeda and affiliated fighters out of a desert refuge the size of Texas in neighboring Mali.


Niger, one of the poorest countries in the world, signed a status-of-forces agreement last month with the United States that has cleared the way for greater American military involvement in the country and provides legal protection to American troops there.


In an interview last month in Niamey, President Mahamadou Issoufou voiced concern about the spillover of violence and refugees from Mali, as well as growing threats from Boko Haram, an Islamist extremist group to the south, in neighboring Nigeria.


French and African troops have retaken Mali’s northern cities, including Timbuktu, Gao and Kidal, but about 2,000 militants have melted back into desert and mountain hideaways and have begun a small campaign of harassment and terror, dispatching suicide bombers, attacking guard posts, infiltrating liberated cities or ordering attacks by militants hidden among civilians.


“Africa Command has positioned unarmed remotely piloted aircraft in Niger to support a range of regional security missions and engagements with partner nations,” Benjamin Benson, a command spokesman in Stuttgart, Germany, said in an e-mail message on Friday.


Mr. Benson did not say how many aircraft or troops ultimately would be deployed, but other American officials have said the base could eventually have as many as 300 United States military service members and contractors.


For now, American officials said Predator drones would at first fly only unarmed surveillance drones, although they have not ruled out conducting missile strikes at some point if the threat worsens.


American officials would like to move the aircraft eventually to Agadez, a city in northern Niger that is closer to parts of northern Mali where cells of Al Qaeda in the Islamic Maghreb and other militants groups are operating. Gen. Carter F. Ham, the leader of the Pentagon’s Africa Command, visited the base last month as part of discussions with Niger’s leaders on closer counterterrorism cooperation.


The new drone base will join a constellation of small airstrips in recent years on the continent, including one in Ethiopia, for surveillance missions flown by drones or turboprop planes designed to look like civilian aircraft.


A handful of unarmed Predator drones will fill a desperate need for more detailed information on regional threats, including the militants in Mali and the unabated flow of fighters and weapons from Libya. General Ham and intelligence analysts have complained that such information has been sorely lacking.


As the United States increased its presence in Niger, Russia sent a planeload of food, blankets and other aid to Mali on Friday, a day after Foreign Minister Sergey V. Lavrov warned about the spread of terrorism in North Africa, which the Russian government has linked to Western intervention in Libya.


Mr. Lavrov met on Thursday with the United Nations special envoy for the region, Romano Prodi, to discuss the situation in Mali, where Russia has supported the French-led effort to oust Islamist militants. But Russia has also blamed the West for the unrest and singled out the French in particular for arming the rebels who ousted the Libyan leader, Col. Muammar el-Qaddafi.


“Particular concern was expressed about the activity of terrorist organizations in the north, a threat to regional peace and security,” the Russian Foreign Ministry said in a statement after the meeting. “The parties agreed that the uncontrolled proliferation of arms in the region in the wake of the conflict in Libya sets the stage for an escalation of tension throughout the Sahel.” The Sahel is a vast region stretching more than 3,000 miles across Africa, from the Atlantic in the west through Sudan in the east.


In a television interview this month, Mr. Lavrov said, “France is fighting against those in Mali whom it had once armed in Libya against Qaddafi.”


Eric Schmitt reported from Washington, and Scott Sayare from Paris. David M. Herszenhorn contributed reporting from Moscow.



Read More..

The Hunger Games: Katniss & Peeta's Victory Tour Look Revealed















02/22/2013 at 06:00 PM EST



They survived the Hunger Games – but will they survive the Victory Tour?

Sporting bridal-like attire, Katniss (Jennifer Lawrence) and Peeta (Josh Hutcherson) pose for a promotional poster for the Victory Tour – which – in the Hunger Games universe – is when the victor of the annual Hunger Games tournament visits each of the fictional Panem's districts.

As true Hunger Games fans know, there is usually only one victor – but Katniss and Peeta rebelled against the Capitol in the first movie, originally opting for joint suicide instead of murder.

The softer look is a deliberate statement, meant to continue the charade that Katniss and Peeta were blinded by love when they rebelled against the rules in the arena.

The second film, Catching Fire, hits theaters Nov. 22.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Eric Garcetti's role in L.A. budget fixes is in dispute









Pressed in the race for mayor of Los Angeles to say how he would fix a persistent budget gap that has led to the gutting of many city services, Eric Garcetti urges voters to look at what he has done in the past.


The onetime City Council president claims credit for reforms that he said cut the City Hall shortfall to just over $200 million from more than $1 billion. He sees "tremendous progress," principally in reducing pension and healthcare costs, and asserts: "I delivered that."


But the truth is in dispute. Although there is not a singular view about any aspect of the city's troubled finances, most of those in the thick of recent budget fights depict Garcetti not as a fiscal hard-liner but as a conciliator who used his leadership position to chart a middle ground on the most significant changes.





Mayor Antonio Villaraigosa, city administrative officer Miguel Santana and one of Garcetti's rivals in the mayoral race, Councilwoman Jan Perry, were among those who pushed for bigger workforce reductions and larger employee contributions toward pensions and healthcare. Labor leaders and their champions on the City Council, including Paul Koretz and Richard Alarcon, sought to cushion the blow for workers.


Garcetti and his supporters say he moderated between those extremes. His critics said he worried too much about process and airing every viewpoint rather than focusing relentlessly on shoring up the city's bottom line.


"It was through the mayor's persistence and steadfast position that we got ongoing concessions," said Santana, the chief budget official for Los Angeles. "It was in collaboration with the council leadership that we finally reached agreements with labor."


The $1-billion-plus deficit Garcetti speaks of shrinking refers not to a single year but to the total of budget gaps that confronted Los Angeles over four years if no corrective action had been taken. The city's fiscal crisis worsened during that time because Garcetti and his fellow council members — including Perry and mayoral candidate Wendy Greuel — approved a city employee pay raise of 25% over five years just before the country stumbled into the recession. (Greuel left the council in 2009 when she was elected city controller.)


Although Garcetti focuses on his role, a portion of the financial improvements were outside his control. The state's elimination of redevelopment agencies in 2012 returned millions to L.A.'s general fund. Tax revenue also ticked upward with the economic recovery.


Garcetti's position as council president from 2006 through 2011 did put him at the center of debate about annual shortfalls that ranged to more than $400 million.


In 2009, he supported an early retirement plan that knocked 2,400 workers off the payroll. "I really pushed that through," the councilman said in an interview. Two participants in confidential contract talks at the heart of the deal had diametrically opposed views. "He made it happen, period," one said; the other offered: "I wouldn't say he was a major mover."


The plan saves the city a maximum of $230 million a year in salary and pension reductions in the short run. But Los Angeles borrowed to spread the costs of the program over 15 years, with current employees and retirees expected to shoulder the cost of the early exits.


The early retirements are expected to do nothing to resolve the long-term "structural deficit" — the $200 million to $400 million a year that Los Angeles spends above what it takes in. And early retirements could even be a net negative in the long run if, as city revenue recovers, new employees are put in those 2,400 empty positions too quickly.


In 2010 the city completed a budget fix that did attack the structural imbalance.


Garcetti's initial proposal called for upping the retirement age for new city employees to 60 from 55 and requiring workers to contribute a minimum of 2% of salary toward their retiree health care.


Budget chief Santana offered a markedly tougher plan. It required a 4% retiree health contribution, halved the health subsidy for retirees and capped pension benefits at 75% of salary instead of 100%. Santana's plan, also for new employees, became the basis of the reform.


Some who served with Garcetti on the council committee that leads employee negotiations pushed for even greater sacrifices. But Garcetti fought against ratcheting up demands on workers, saying it would be useless to approve a plan that would not survive subsequent union votes.


The councilman's greatest contribution may have come after city leaders set their position on pensions. Garcetti took the unusual step of visiting groups of workers. Some employees booed. Some asked him why city lawmakers, among the highest paid in the nation at $178,000 a year, didn't cut their own salaries.


"There was a lot of anger," said a labor leader who spoke on condition of anonymity because that union has not endorsed in the race. "But Eric talked to people as if they were adults and stayed until he answered all their questions. People appreciated him ... taking that kind of heat."


Matt Szabo, a former deputy mayor who helped negotiate with labor, said Garcetti deserved "every bit of credit" he has claimed for deficit reduction. "He knew he was running for mayor, and he was doing the right thing, but it was something that was going to cost him later" in terms of union support, said Szabo, who is running to replace Garcetti on the council.


Most of the employee groups that have endorsed thus far in the mayor's race have come out for Greuel. One political advantage for the controller: She left the council in 2009, before the city began making its toughest demands on workers.


Garcetti found himself stuck the middle again with another 2010 vote, this one over the elimination of 232 jobs — most of them in libraries and day care operations at city parks. Garcetti voted for the layoffs. Later he voted to reconsider, though he said recently that he intended only to re-air the issue, not to keep the workers on the job.


Labor leaders faulted Garcetti for giving the appearance he might be ready to save the jobs when he really wasn't. The reductions remain a sore point, because a "poison pill" in the contract required that any layoffs be accompanied by immediate pay raises for remaining city employees. Fierce disagreement remains over whether the layoffs saved the city any money.


"That became part of the negative picture" of Garcetti, said one labor leader, who asked not to be named out of concern about alienating a possible future mayor. The candidate said in an interview that he frequently found himself hewing a middle ground between some colleagues "who simply hope more revenue would come in" and others who wanted to use an "ax," making indiscriminate cuts. He added: "To me, both views were equally unacceptable."


Critics find Garcetti too malleable, ready to shift to the last argument he has heard. But others appreciate his quest for the middle, saying the fact he sometimes irritated both budget hard-liners and unions showed he had taken a reasoned approach.


"The criticism of Eric is also sort of the good news," said one of the union reps. "He has this very process-y, kumbaya, can't-we-all-get-along style. It drove us all crazy. But now I really miss it because it seems to be all politics over policy."


james.rainey@latimes.com





Read More..

15 G.O.P. Senators Ask Obama to Withdraw Hagel Nomination


WASHINGTON — A group of 15 Republican senators insisted on Thursday that President Obama withdraw the nomination of Chuck Hagel to be defense secretary, the latest move in a contentious battle to block the confirmation of their former colleague.


But even as Republican senators tried to throw up another obstacle, Senate Democrats said they were pushing ahead with plans to hold a final up-or-down vote on the nomination no later than Wednesday.


Should that vote proceed as planned, Mr. Hagel’s confirmation appears assured. Several Republicans have said that they intend to drop their attempts to filibuster the nomination.


But given how deeply divided Mr. Hagel’s nomination has left the Senate, the outlook in the immediate term is murky.


Many Republicans, like the 15 who wrote to the president on Thursday, signaled that they would not let the issue die quietly. And those who have said that they would ultimately not support a filibuster, like Deb Fischer of Nebraska and Richard Shelby of Alabama, were choosing their words carefully.


Saying that Mr. Hagel’s confirmation would be “unprecedented” because of near-unanimous opposition from Republicans, the group of 15 senators urged Mr. Obama to pick another candidate.


“Over the last half-century, no secretary of defense has been confirmed and taken office with more than three senators voting against him,” they wrote. “The occupant of this critical office should be someone whose candidacy is neither controversial or divisive.”


Signing the letter were John Cornyn of Texas, the No. 2 Senate Republican; Lindsey Graham and Tim Scott of South Carolina; Roger Wicker of Mississippi; David Vitter of Louisiana; Ted Cruz of Texas; Mike Lee of Utah; Patrick J. Toomey of Pennsylvania; Marco Rubio of Florida; Dan Coats of Indiana; Ron Johnson of Wisconsin; James E. Risch of Idaho; John Barrasso of Wyoming; and Tom Coburn and James Inhofe of Oklahoma.


Members of the group cited a litany of objections, including Mr. Hagel’s unimpressive showing at his confirmation hearing, which drew criticism from members of both parties, and what they said was his “dangerous” posture toward dealing with Iran.


The level of derision directed at Mr. Hagel from Republicans has been striking not just because defense secretaries are usually confirmed on a simple up-or-down vote, but also because Mr. Hagel, a Republican, served with many of them in the Senate until 2008.


“Senator Hagel’s performance at his confirmation hearing was deeply concerning, leading to serious doubts about his basic competence to meet the substantial demands of the office,” they said.


Senate Republicans narrowly blocked a vote on Mr. Hagel’s confirmation last week in a filibuster, forcing Democrats to put the matter off until senators return from recess next week.


Republicans have been using the filibuster to prevent final consideration of the nomination by refusing to end debate on it, a procedural step that requires 60 senators to vote in the affirmative.


But some Republicans, including Senator John McCain of Arizona, have since said that they will drop their objections. Mr. McCain was firm, saying on Sunday, “I don’t believe that we should hold up his nomination any further.”


Others, like Mr. Graham, Mr. Shelby and Ms. Fischer, have said that while they do not support a filibuster, they believe that the senators should have ample time to consider their votes, leaving themselves open to voting not to end debate next week.


Only one more Republican “yes” vote would be needed to cut off debate and carry through with a final vote if all the Republicans who voted to end the filibuster last week voted to do so again.


Because Mr. Hagel has the support of Senate Democrats, who control 55 seats, he is likely to clear a final vote.


If Senate Democrats move ahead with a vote and get the 60 votes necessary to end debate, Mr. Hagel could be confirmed as early as Tuesday. But because of procedural rules, any Republican could still delay the vote until Wednesday.


A new voice chimed in on the debate on Thursday. Bob Dole, the former Senate majority leader and, like Mr. Hagel, a decorated veteran, urged his fellow Republicans to put aside their objections.


“Hagel’s wisdom and courage make him uniquely qualified to be secretary of defense and lead the men and women of our armed forces,” Mr. Dole said, adding that he would be “an exceptional leader at an important time.”


Read More..

Survivor's Whitney Duncan: From Secret Marriage to Divorce to Engagement!















02/21/2013 at 06:45 PM EST







Whitney Duncan and Keith Tollefson


Monty Brinton/CBS; Inset: Courtesy Whitney Duncan


Country singer and former Survivor contestant Whitney Duncan is engaged – and this time it's not a secret.

"I'm going to marry this man," Duncan Tweeted on Feb. 14 shortly after announcing her engagement to her fellow Survivor tribemate Keith Tollefson.

Duncan, 28, was secretly married when she met and fell for Tollefson, 27, on Survivor: South Pacific in the summer of 2011 but now the tribemates are headed down the aisle.

"He did good," Duncan wrote on Facebook along with a photo of her sparkling engagement ring of interlocking circles in a complex pattern.

Survivor's Whitney Duncan: From Secret Marriage to Divorce to Engagement!| Couples, Engagements, Survivor, Survivor: South Pacific, TV News

Whitney Duncan and Keith Tollefson

Courtesy Whitney Duncan

The "Skinny Dippin' " singer portrayed herself as single on the 23rd season of the CBS reality show, but she had actually been married to Donny Fallgatter, lead singer for the band KingBilly, since August 2010.

Fallgatter and Duncan had kept their marriage a secret from even friends and family until Duncan confessed her feelings for Tollefson to Fallgatter during a phone call made just before she returned from filming Survivor, a source close to the couple told PEOPLE in 2011.

The country couple's divorce proceedings were complete in November 2011 and now Duncan and Tollefson – a self-described environmentalist – are happily celebrating their impending nuptials.

"Thanks to everyone for the best wishes on mine and @whitneyduncan's engagement," Tollefson tweeted. "I know real original proposing on Valentines day ha."

Read More..

Flu shot doing poor job of protecting older people


ATLANTA (AP) — It turns out this year's flu shot is doing a startlingly dismal job of protecting older people, the most vulnerable age group.


The vaccine is proving only 9 percent effective in those 65 and older against the harsh strain of the flu that is predominant this season, the Centers for Disease Control and Prevention said Thursday.


Health officials are baffled as to why this is so. But the findings help explain why so many older people have been hospitalized with the flu this year.


Despite the findings, the CDC stood by its recommendation that everyone over 6 months get flu shots, the elderly included, because some protection is better than none, and because those who are vaccinated and still get sick may suffer less severe symptoms.


"Year in and year out, the vaccine is the best protection we have," said CDC flu expert Dr. Joseph Bresee.


Overall, across the age groups studied, the vaccine's effectiveness was found to be a moderate 56 percent, which means those who got a shot have a 56 percent lower chance of winding up at the doctor with the flu. That is somewhat worse than what has been seen in other years.


For those 65 and older, the vaccine was only 27 percent effective against the three strains it is designed to protect against, the worst level in about a decade. It did a particularly poor job against the tough strain that is causing more than three-quarters of the illnesses this year.


It is well known that flu vaccine tends to protect younger people better than older ones. Elderly people have weaker immune systems that don't respond as well to flu shots, and they are more vulnerable to the illness and its complications, including pneumonia.


But health officials said they don't know why this year's vaccine did so poorly in that age group.


One theory, as yet unproven, is that older people's immune systems were accustomed to strains from the last two years and had more trouble switching gears to handle this year's different, harsh strain.


The preliminary data for senior citizens is less than definitive. It is based on fewer than 300 people scattered among five states.


But it will no doubt surprise many people that the effectiveness is that low, said Michael Osterholm, a University of Minnesota infectious-disease expert who has tried to draw attention to the need for a more effective flu vaccine.


Among infectious diseases, flu is considered one of the nation's leading killers. On average, about 24,000 Americans die each flu season, according to the CDC.


This flu season started in early December, a month earlier than usual, and peaked by the end of year. Hospitalization rates for people 65 and older have been some of the highest in a decade, at 146 per 100,000 people.


Flu viruses tend to mutate more quickly than others, so a new vaccine is formulated each year to target the strains expected to be the major threats. CDC officials have said that in formulating this year's vaccine, scientists accurately anticipated the strains that are circulating this season.


Because of the guesswork involved, scientists tend to set a lower bar for flu vaccine. While childhood vaccines against diseases like measles are expected to be 90 or 95 percent effective, a flu vaccine that's 60 to 70 percent effective in the U.S. is considered pretty good. By that standard, this year's vaccine is OK.


For senior citizens, a flu vaccine is considered pretty good if it's in the 30 to 40 percent range, said Dr. Arnold Monto, a University of Michigan flu expert.


A high-dose version of the flu shot was recently made available for those 65 and older, but the new study was too small to show whether that has made a difference.


The CDC estimates are based on about 2,700 people who got sick in December and January. The researchers traced back to see who had gotten shots and who hadn't. An earlier, smaller study put the vaccine's overall effectiveness at 62 percent, but other factors that might have influenced that figure weren't taken into account.


The CDC's Bresee said there is a danger in providing preliminary results because it may result in people doubting — or skipping — flu shots. But the figures were released to warn older people who got shots that they may still get sick and shouldn't ignore any serious flu-like symptoms, he said.


___


Online:


CDC report: http://www.cdc.gov/mmwr


Read More..